Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8601340 | 0.90 | GPR174 (0.72) | GPR174KMT2AMEN1LMNACYP1A2 | |
| SCHEMBL10608486 | 0.86 | KMT2A (0.71) | KMT2AMEN1LMNACYP1A2TDP1 | |
| SCHEMBL839926 | 0.84 | MEN1 (0.69) | GPR174KMT2AMEN1LMNACYP1A2 | |
| SCHEMBL22388441 | 0.84 | GPR174 (1.00) | GPR174KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL12678535 | 0.83 | MEN1 (0.67) | KMT2AMEN1LMNACYP1A2TDP1 | |
| SCHEMBL1064813 | 0.82 | KMT2A (0.71) | KMT2AMEN1LMNACYP1A2TDP1 | |
| SCHEMBL11111056 | 0.82 | ALDH1A1 (0.80) | KMT2AMEN1LMNACYP1A2TDP1 | |
| SCHEMBL18470893 | 0.81 | ALDH1A1 (0.69) | GPR174KMT2AMEN1LMNACYP1A2 | |
| SCHEMBL10338925 | 0.81 | GPR174 (0.58) | GPR174KMT2AMEN1LMNAMAPT | |
| SCHEMBL8657499 | 0.81 | NPC1 (0.70) | GPR174KMT2AMEN1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393811-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE DERIVATIVES | Pfizer Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089686-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC | 2010-08-05 | — | — | US | disclosed |
| US-5889078-A | HOMO OR COPOLYMERISING ACRYLIC OR METHACRYLIC ACID DERIVATIVE FORMED BY REACTING ACID DERIVATIVE WITH DRUGS-ACETAMINOPHEN, NICOTINAMIDE, FLUOROURACIL, AMPHOTERICIN B, METHYLDOPA AND CEPHALEXIN BY GRINIDNG, RUBBING AND HIGH SPEED VIBRATION | EISAI CO., LTD. (JP) | 1999-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | CDK7, DPYD, DHFR | GPR174 893/4885KMT2A 3053/4885MEN1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.